The cardiac Fabry disease are early, frequent and severe, dominated by the frequency of left
ventricular hypertrophy. They are responsible for a high morbidity and mortality, reducing
life expectancy of 15 to 20 years for men. Fabry disease and heart attacks are still
diagnosed late. This delay in diagnosis is due to the non-specificity of clinical,
electrocardiographic and echocardiographic disease, but also by a certain ignorance of this
pathology in the medical community. The importance of early diagnosis of Fabry disease and
heart disease is well established: enzyme replacement therapy is most effective when
instituted early, before the onset of irreversible damage such as fibrosis. With the blotter,
we now have a simple and robust screening tool for Fabry disease, achievable consultation.
Targeted educational interventions to physicians have shown their effectiveness in improving
the screening and diagnosis of rare diseases. We offer a prospective observational type
before / after study, which aims to assess the value of an educational brochure for
cardiologists to improve the screening and diagnosis of Fabry disease in Normandy.